Defining ‘Response’ in Antipsychotic Drug Trials: Recommendations for the Use of Scale-Derived Cutoffs

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Neuropsychopharmacology

• Publication date

  2007-02-07

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1038/sj.npp.1301325PMID 17287825
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Linking the PANSS, BPRS, and CGI: Clinical Implications

  2006cited by this paper
• Time course for antipsychotic treatment response in first-episode schizophrenia.

  2006cited by this paper
• The Relative Sensitivity of the Clinical Global Impressions Scale and the Brief Psychiatric Rating Scale in Antipsychotic Drug Trials

  2006cited by this paper
• Remission in schizophrenia: proposed criteria and rationale for consensus.

  2005cited by this paper
• What does the PANSS mean?

  2005cited by this paper
• Clinical implications of Brief Psychiatric Rating Scale scores.

  2005cited by this paper
• A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia

  2004cited by this paper
• A meta-analysis of the efficacy of second-generation antipsychotics.

  2003cited by this paper
• Issues in the selection of a summary statistic for meta‐analysis of clinical trials with binary outcomes

  2002cited by this paper
• Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials.

  2002cited by this paper
• Clinical profile of an atypical antipsychotic: risperidone.

  2002cited by this paper
• Amisulpride vs. Risperidone in Chronic Schizophrenia: Results of a 6-month Double-blind Study

  2002influential reference
• Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine.

  2001cited by this paper
• A comparison of clozapine to chlorpromazine affecting serum glutamate levels and their relationship with clinical efficacy in schizophrenia

  2001cited by this paper
• A comparison of clozapine to chlorpromazine affecting serum glutamate levels and their relationship with clinical efficacy in schizophrenia

  2001cited by this paper
• Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group.

  2000cited by this paper
• Long‐term safety and efficacy of amisulpride in subchronic or chronic schizophrenia

  2000influential reference
• Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group*

  2000influential reference
• Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group.

  1999influential reference
• [The problem of therapeutic efficacy indices. 2. Description of the indices].

  1999cited by this paper
• [The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use].

  1999cited by this paper
• Amisulpride, an atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose‐ranging study vs. haloperidol

  1998influential reference
• Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology – a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist

  1998influential reference
• Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group.

  1998cited by this paper
• Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol

  1997influential reference
• Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.

  1997cited by this paper
• Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group.

  1997cited by this paper
• A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia

  1997cited by this paper
• Meta-analysis: Principles and procedures

  1997cited by this paper
• Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial.

  1996cited by this paper
• 3 The Cochrane Library

  1996cited by this paper
• Olanzapine versus Placebo and Haloperidol

  1996cited by this paper
• Risperidone in the Treatment of Patients with Chronic Schizophrenia: a Multi-National, Multi-Centre, Double-Blind, Parallel-Group Study versus Haloperidol

  1995cited by this paper
• Risperidone in the treatment of schizophrenia.

  1994cited by this paper
• The brief psychiatric rating scale: effect of scaling system on clinical response assessment.

  1994cited by this paper
• Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations

  1993cited by this paper
• A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.

  1993cited by this paper
• Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double‐blind comparative study

  1992cited by this paper
• Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

  1988cited by this paper
• The positive and negative syndrome scale (PANSS) for schizophrenia.

  1987cited by this paper
• The Brief Psychiatric Rating Scale

  1962cited by this paper

• Associations between glutamate and cerebral blood flow in treatment-resistant schizophrenia during clozapine treatment.

  2026cites this paper
• Patient Life Engagement and Metabolic Profile Improve After Switching from First-/Second-Generation Antipsychotics to Brexpiprazole: A Real-World Study in Patients with Schizophrenia

  2025cites this paper
• Urban built density and brain connectivity predict antipsychotic response in a sex-specific manner in Schizophrenia.

  2025cites this paper
• COSMIN systematic review and meta-analysis of the measurement properties of the PANSS-6.

  2025cites this paper
• COSMIN systematic review and meta-analysis of the measurement properties of the Positive and Negative Syndrome Scale (PANSS)

  2025cites this paper
• Methods to address functional unblinding of raters in CNS trials

  2025cites this paper
• Evaluation of atypical antipsychotic-induced mitochondrial dysfunction in patients with schizophrenia: a randomised controlled trial protocol

  2025cites this paper
• Response to the Letter to the Editor "Reflections on a study of electroconvulsive therapy for clozapine-refractory schizophrenia" (Jolly et al. Schizophrenia Research, 267 (2024) 32-33).

  2025cites this paper
• Response to clozapine in treatment resistant schizophrenia is related to alterations in regional cerebral blood flow

  2024cites this paper
• Prediction of antipsychotics efficacy based on a polygenic risk score: a real-world cohort study

  2024cites this paper
• Incremental predictive value of genetic risk and functional brain connectivity in determining antipsychotic response in schizophrenia.

  2024cites this paper
• Melatonin for Sleep Quality and Occupational Cognitive Performance in Shift Workers with Low Sleep Quality: A Randomized, Double‐Blind, Placebo‐Controlled Clinical Trial

  2024cites this paper
• Positive Effects of Uric Acid on White Matter Microstructures and Treatment Response in Patients With Schizophrenia.

  2024cites this paper
• Identifying differential predictors for treatment response to amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia: Results of the COMBINE-study.

  2024cites this paper
• Crocus sativus (saffron) adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled trial.

  2024cites this paper
• Clinical and Sociodemographic Correlations with Neurological Soft Signs in Hospitalized Patients with Schizophrenia: A Preliminary Longitudinal Study

  2024cites this paper
• Factors associated with improved outcomes in the first psychotic episode at a specialized outpatient clinic in northeastern Brazil

  2024cites this paper
• Pentoxifylline adjunct to risperidone for negative symptoms of stable schizophrenia: a randomized, double-blind, placebo-controlled trial

  2024cites this paper
• GAPi: A description of the initiative for early psychosis intervention in Latin America and the short- to medium-term outcomes in early psychosis patients.

  2024cites this paper
• Psychotic disorders as a framework for precision psychiatry

  2023cites this paper
• Optimising plasma clozapine levels to improve treatment response: an individual patient data meta-analysis and receiver operating characteristic curve analysis

  2023cites this paper
• L-Theanine adjunct to risperidone in the treatment of chronic schizophrenia inpatients: a randomized, double-blind, placebo-controlled clinical trial

  2023cites this paper
• Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial.

  2023cites this paper
• A potential issue with PANSS responder analysis.

  2023cites this paper
• Cerebral blood flow in striatum is increased by partial dopamine agonism in initially antipsychotic-naïve patients with psychosis

  2023cites this paper
• Clinical response to treatment with a partial dopamine agonist is related to changes in reward processing.

  2023cites this paper
• The Trajectory of Prefrontal GABA levels in Initially Antipsychotic-Naïve Patients with Psychosis during Two Years Treatment and associations with Striatal Cerebral Blood Flow and Outcome.

  2023cites this paper
• Exercise as an add-on treatment in individuals with schizophrenia: Results from a large multicenter randomized controlled trial.

  2023cites this paper
• Targeting metacognitive change mechanisms in acute inpatients with psychotic symptoms: feasibility and acceptability of a modularized group intervention

  2023cites this paper
• Early Efficacy of Antipsychotic Medications at Week 2 Predicts Subsequent Responses at Week 6 in a Large-scale Randomized Controlled Trial

  2022cites this paper
• A longitudinal investigation of GABA, glutamate, and glutamine across the insula during antipsychotic treatment of first-episode schizophrenia.

  2022cites this paper
• Early Markers in Resistant Schizophrenia: Effect of the First Antipsychotic Drug

  2022cites this paper
• Case Report: Long-Acting Oral Cariprazine

  2022cites this paper
• Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia: a 12-week randomized, double-blind, placebo-controlled trial

  2022cites this paper
• Anterior cingulate glutamate metabolites as a predictor of antipsychotic response in first episode psychosis: data from the STRATA collaboration

  2022cites this paper
• Amisulpride Augmentation Therapy Improves Cognitive Performance and Psychopathology in Clozapine-resistant Treatment-refractory Schizophrenia (CTRS): a 12-week Randomized, Double-blind, Placebo-controlled Trial

  2022cites this paper
• Predicting Treatment Response in Schizophrenia With Magnetic Resonance Imaging and Polygenic Risk Score

  2022cites this paper
• Subcortical volume reduction and cortical thinning 3 months after switching to clozapine in treatment resistant schizophrenia

  2022cites this paper
• Reduced Platelet MAO-B Activity Is Associated with Psychotic, Positive, and Depressive Symptoms in PTSD

  2022cites this paper
• Trajectories of response in schizophrenia-spectrum disorders: A one-year prospective cohort study of antipsychotic effectiveness

  2022cites this paper
• Audio-digital recordings to assess ratings reliability in clinical trials of schizophrenia.

  2021cites this paper
• Toward personalized medicine in schizophrenia: Genetics and epigenetics of antipsychotic treatment.

  2021cites this paper
• Time‐course of clinical symptoms in young people at ultra‐high risk for transition to psychosis

  2021cites this paper
• Benefits and harms of Risperidone and Paliperidone for treatment of patients with schizophrenia or bipolar disorder: a meta-analysis involving individual participant data and clinical study reports

  2021cites this paper
• Baseline levels of C-reactive protein and proinflammatory cytokines are not associated with early response to amisulpride in patients with First Episode Psychosis: the OPTiMiSE cohort study

  2021cites this paper
• Site-independent confirmation of primary site-based PANSS ratings in a schizophrenia trial.

  2021cites this paper
• How Efficacious Are Antipsychotic Drugs for Schizophrenia? An Interpretation Based on 13 Effect Size Indices.

  2021cites this paper
• Changes in Brain Glutamate on Switching to Clozapine in Treatment-Resistant Schizophrenia

  2021cites this paper
• Antipsychotic drugs increase Neuregulin1β1 serum levels in first-episode drug-naïve patients and chronic schizophrenia with suggestions for improving the treatment of psychotic symptoms

  2021cites this paper
• Influence of cytochrome P450 2D6 polymorphism on hippocampal white matter and treatment response in schizophrenia

  2021cites this paper
• Alcohol related phenotypes and platelet serotonin concentration.

  2021cites this paper
• Appropriate Number of Treatment Sessions in Virtual Reality-Based Individual Cognitive Behavioral Therapy for Social Anxiety Disorder

  2021cites this paper
• Using Machine-Learning Techniques to Identify Responders vs. Non-responders in Randomized Clinical Trials.

  2020cites this paper
• Longitudinal trajectory analysis of antipsychotic response in patients with schizophrenia: 6-week, randomised, open-label, multicentre clinical trial

  2020cites this paper
• Predicting responses to electroconvulsive therapy in schizophrenia patients undergoing antipsychotic treatment: Baseline functional connectivity among regions with strong electric field distributions.

  2020cites this paper
• Defining Treatment Response, Remission, Relapse, and Recovery in First-Episode Psychosis: A Survey among Korean Experts

  2020influential citation
• Predicting individual improvement in schizophrenia symptom severity at 1‐year follow‐up: Comparison of connectomic, structural, and clinical predictors

  2020cites this paper
• Clozapine and paliperidone palmitate antipsychotic combination in treatment-resistant schizophrenia and other psychotic disorders: A retrospective 6-month mirror-image study

  2020cites this paper
• Impact of duration of untreated psychosis in short‐term response to treatment and outcome in antipsychotic naïve first‐episode psychosis

  2019cites this paper
• Antipsychotic drugs v. barbiturates or benzodiazepines used as active placebos for schizophrenia: a systematic review and meta-analysis

  2019cites this paper
• Remission from antipsychotic treatment in first episode psychosis related to longitudinal changes in brain glutamate

  2019cites this paper
• What happens with schizophrenia patients after their discharge from hospital? Results on outcome and treatment from a “real-world” 2-year follow-up trial

  2019cites this paper
• Treatment response after 6 and 26 weeks is related to baseline glutamate and GABA levels in antipsychotic-naïve patients with psychosis

  2019cites this paper
• Metabolic-inflammatory status as predictor of clinical outcome at 1-year follow-up in patients with first episode psychosis.

  2019cites this paper
• Remission in schizophrenia - What are we measuring? Comparing the consensus remission criteria to a CGI-based definition of remission and to remission in major depression.

  2019cites this paper
• The relationship between grey matter volume and striatal dopamine function in psychosis: a multi-modal 18F-DOPA PET and voxel-based morphometry study

  2019cites this paper
• What We Know and Still Need to Know about Gender Aspects of Delusional Disorder: A Narrative Review of Recent Work

  2019cites this paper
• Prepartum Relapses or Treatment Resistance: A Case of Unipolar Mania

  2019cites this paper
• A systematic review of the operational definitions for antipsychotic response in delusional disorder

  2018cites this paper
• How Many Patients With Schizophrenia Do Not Respond to Antipsychotic Drugs in the Short Term? An Analysis Based on Individual Patient Data From Randomized Controlled Trials

  2018cites this paper
• Therapeutic Drug Monitoring of Second-Generation Antipsychotics for the Estimation of Early Drug Effect in First-Episode Psychosis: A Cross-sectional Assessment

  2018cites this paper
• Defining Treatment Response and Remission in Youth Anxiety: A Signal Detection Analysis With the Multidimensional Anxiety Scale for Children.

  2018cites this paper
• ABCB1 and CYP2D6 polymorphisms and treatment response of psychotic patients in a naturalistic setting

  2018cites this paper
• Comparing Schizophrenia Patients With a Predicted High/Low Risk of Nonresponse Receiving Treatment with Ziprasidone and Haloperidol: A Randomized-Controlled Study

  2018cites this paper
• Response rates in patients with schizophrenia and positive symptoms receiving cognitive behavioural therapy: a systematic review and single-group meta-analysis

  2018cites this paper
• Baseline serum vascular endothelial growth factor levels predict treatment response to antipsychotic medication in patients with schizophrenia.

  2018cites this paper
• Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre 1H-MRS study (OPTiMiSE)

  2018cites this paper
• Neuromodulation in response to electroconvulsive therapy in schizophrenia and major depression.

  2017cites this paper
• Effects of Exercise on Serum Triglycerides and Symptoms of Schizophrenia

  2017cites this paper
• How well do patients with a first episode of schizophrenia respond to antipsychotics: A systematic review and meta-analysis.

  2017cites this paper
• Add-on Antidepressants in the Naturalistic Treatment of Schizophrenia Spectrum Disorder – When, Who, and How?

  2017cites this paper
• New evidence in support of staging approaches in schizophrenia: Differences in clinical profiles between first episode, early stage, and late stage.

  2017cites this paper
• Acceptance and Commitment Therapy for Inpatients with Psychosis (the REACH Study): Protocol for Treatment Development and Pilot Testing

  2017cites this paper
• One-year symptom trajectories in patients with stable schizophrenia maintained on antipsychotics versus placebo: meta-analysis.

  2017cites this paper
• A Pilot Study of the Usefulness of a Single Olanzapine Plasma Concentration as an Indicator of Early Drug Effect in a Small Sample of First-Episode Psychosis Patients

  2017cites this paper
• Bitopertin in Negative Symptoms of Schizophrenia-Results From the Phase III FlashLyte and DayLyte Studies.

  2017cites this paper
• Connectomic correlates of response to treatment in first-episode psychosis

  2017cites this paper
• Defining cognitive-behavior therapy response and remission in pediatric OCD: a signal detection analysis of the Children’s Yale-Brown Obsessive Compulsive Scale

  2016cites this paper
• Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis.

  2016cites this paper
• Factors associated with relapse in schizophrenia despite adherence to long-acting injectable antipsychotic therapy

  2016cites this paper
• The GRM7 gene, early response to risperidone, and schizophrenia: a genome-wide association study and a confirmatory pharmacogenetic analysis

  2016cites this paper
• Pretreatment levels of the fatty acid handling proteins H-FABP and CD36 predict response to olanzapine in recent-onset schizophrenia patients.

  2016cites this paper
• Acetyl-L-Carnitine Augmentation of Clozapine in Partial-Responder Schizophrenia: A 12-Week, Open-Label Uncontrolled Preliminary Study

  2016cites this paper
• Dose-response meta-analysis of differences in means

  2016cites this paper
• A randomized controlled study of the efficacy of six-month supplementation with concentrated fish oil rich in omega-3 polyunsaturated fatty acids in first episode schizophrenia.

  2016cites this paper
• Monoamine oxidase and agitation in psychiatric patients.

  2016cites this paper
• Atypical antipsychotic treatment increases glial cell line-derived neurotrophic factor serum levels in drug-free schizophrenic patients along with improvement of psychotic symptoms and therapeutic effects.

  2016cites this paper
• Robust inference for responder analysis: Innovative clinical trial design using a minimum p-value approach

  2016cites this paper
• Antipsychotic treatment and psychosocial functioning in schizophrenia – results from Romanian cohort of EUFEST study

  2016cites this paper
• Challenging the understanding of significant improvement and outcome in schizophrenia – the concept of reliable and clinically significant change methods

  2016cites this paper